Zacks Investment Research
01 Oct 2026, 22:50 UTC · 18h ago
Verdict
Headline leans bullish. We score MRNA −0.40 across three claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Moderna is projected to report quarterly earnings of -$1.36 per share, a year-over-year decline of 166.67%.
Priced inconsensus estimate cited in analysis
More negative than 86% of claims this week
Quarterly revenue for Moderna is estimated at $888.78 million, down 12.52% from the year-ago period.
Priced in
Continue reading
5 related stories
More negative than 70% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
So whatThe revenue decline contributes to the projected quarterly EPS loss of $1.36.
More negative than 78% of claims this week
Analysts expect full-year earnings of -$8.5 per share and revenue of $2.11 billion.
Priced inconsensus estimates for full year
So whatWhile revenue is expected to grow 8.31% for the year, the company remains deeply unprofitable on an annual basis.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 70% of ticker scores this week
The company faces projected year-over-year declines in both earnings and revenue, and carries a 'Hold' rank.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
−0.2%
Price flat so far
$188.59 vs $188.94 close before publication (Oct 1) · not market-adjusted
MRNA chart →
